News

January 10, 2018: TECHFIELDS HAS BEGUN PHASE 3 CLINICAL TRIALS OF X0002

Date:2018-02-10View: 21

Techfields has begun a Phase III clinical trial of a novel drug-X0002, TF-X0002-31(Bettermove-1), in 56 sites in the US for the treatment of knee OA. The study title is:

A Phase 3, Multicenter, 22-Week, Double-blind and 30-Week Open Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of X0002 Spray in Relief of the Signs and Symptoms of Subjects with Osteoarthritis of the Knee.